← SynDRA
TIVOZANIB
SynDRA canonical compound SYN0024931 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | PDGFRB |
|---|
| Mechanism of action | VEGFR inhibitor |
|---|
| Indication | renal cell carcinoma (RCC) |
|---|
| Disease area | oncology |
|---|
All known targets
- FLT4
- FLT1
- KDR
- PDGFRB
- KIT
- PDGFRA
- FRK
- RIPK3
- RIPK2
- RET
- PTK6
- PEBP1
Mechanisms of action (all sources)
- VEGFR inhibitor
- FLT1 INHIBITOR
- Vascular endothelial growth factor receptor inhibitor
- FLT4 INHIBITOR
- KDR INHIBITOR
- KIT INHIBITOR
- Stem cell growth factor receptor inhibitor
- PDGFRB INHIBITOR
- Platelet-derived growth factor receptor beta inhibitor
- FLT4 MODULATOR
- KDR MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SRC
- TEK
- YES1
- MAPK1
- MAPK3
- SLC6A3
- EGFR
- SYK
- PCYT1A
- PGRMC1
- PGR
- PFKP
- PDXK
- PDPK1
- PDE4D
- PDE3A
- PAK5
- PASK
- PAK6
- PIM1
- PAK4
- PAK3
- PAK2
- PAICS
- OPA1
- OLA1
- PHKG2
- AAK1
- PIM2
- PRKAA1
- PRKCD
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKACA
- PLK4
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP3A7
- FGF2
- IFNB1
- IFNG
- KSYK
- NSD2
- TP53
Drug classes
- Tyrosine Kinase Inhibitors
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Kinase Inhibitor
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- FOTIVDA
- Fotivda
- tivozanib hydrochloride monohydrate
- fotivda
- Kil8951
- AV-951
- KRN951
- KRN-951
- ASP-4130
- Kil-8951
- KIL8951
- OPHTHOTECH
- TIVOZANIB (AV-951)
- TIVOZANIB (OPHTHALMIC)
- TIVOZANIB HCL
- ASP4130/AV-951
- AV 951
- Tivozanib (AV-951)
- KRN 951
- AV951
- CHEMBL1289494
- AV-951;KRN951
- 172030934T
- Tivozanib [USAN]
- Tivozanib [USAN:INN]
- 4ase
- AV9
- UNII-172030934T
- AV-951,Tivozanib
- Tivozanib(AV-951)
- TIVOZANIB [INN]
- AV951 cpd
- Tivozanib (USAN/INN)
- Tivozanib - AV-951
- TIVOZANIB [WHO-DD]
- MLS006011287
- SCHEMBL172883
- GTPL6058
Reported adverse events
- Fatigue
- Hypertension
- Hypothyroidism
- Rash
- Stomatitis
- Amylase increased
- Back pain
- Cough
- Lipase increased
- Nausea
- Proteinuria
- Vomiting
Look up TIVOZANIB in the interactive SynDRA portal →